ArticleScientific reports2026
Protection of multiple aspects of Alzheimer's disease pathology using dietary supplementation with taurine.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
As Alzheimer’s disease (AD) continues to rise amongst the aging population, preventative measures such as dietary or lifestyle changes represent an attractive option to mitigate the burden. Taurine, known for its antioxidant and anti-inflammatory properties, may also play a neuroprotective role. This study investigates the protective effects of taurine supplementation in 5xFAD mice. Taurine was administered through drinking water at doses of 0, 500, 1000, 2000, 4000 mg/kg/day, with no change in water consumption or body mass was observed. Postmortem markers of neuroinflammation using cytokine profiling demonstrated that 2000 mg/kg/day was effective at invoking a protective response against AD progression. An acute dose of this concentration, in older mice, was also sufficient at protecting the dentate gyrus against gliosis and preventing volume loss. Supplementation of taurine for 1–2 months in older mice also led to a small reduction in the Aβ42 burden. This suggests that in pre-clinical models of AD, both long-term and acute administration of taurine can mitigate pathological AD characteristics. High-resolution magic angle spinning magnetic resonance spectroscopy (HRMAS-MRS) was used to analyze and differentiate the molecular profile of 3 key AD-affected regions: frontal cortex, ventral and dorsal hippocampus. Significant changes in 5 metabolites (GABA, glutamate, NAA, aspartate and scyllo-inositol) were observed in AD at two different ages (3–4 months and 8 months). Taurine supplementation changed the values of a number of metabolites, including NAA and glutamate, to levels closer to that of the wild-type mice, suggesting neuroprotection of these metabolites. Overall, these findings support dietary taurine supplementation as a promising preventative strategy for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.